Galderma Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GALDERMA LABS, and when can generic versions of GALDERMA LABS drugs launch?
GALDERMA LABS has twenty-seven approved drugs.
There are seventy-six US patents protecting GALDERMA LABS drugs.
There are five hundred and one patent family members on GALDERMA LABS drugs in thirty-seven countries and one hundred and fifty-seven supplementary protection certificates in eighteen countries.
Summary for Galderma Labs
International Patents: | 501 |
US Patents: | 76 |
Tradenames: | 18 |
Ingredients: | 15 |
NDAs: | 27 |
Drugs and US Patents for Galderma Labs
Expired US Patents for Galderma Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Galderma Labs Lp | DIFFERIN | adapalene | CREAM;TOPICAL | 020748-001 | May 26, 2000 | RE34440 | See Plans and Pricing |
Galderma Labs Lp | ORACEA | doxycycline | CAPSULE;ORAL | 050805-001 | May 26, 2006 | 7,232,572 | See Plans and Pricing |
Galderma Labs Lp | CLOBEX | clobetasol propionate | LOTION;TOPICAL | 021535-001 | Jul 24, 2003 | 6,106,848 | See Plans and Pricing |
Galderma Labs | CLOBEX | clobetasol propionate | SHAMPOO;TOPICAL | 021644-001 | Feb 5, 2004 | 8,066,975 | See Plans and Pricing |
Galderma Labs Lp | ORACEA | doxycycline | CAPSULE;ORAL | 050805-001 | May 26, 2006 | 7,211,267 | See Plans and Pricing |
Galderma Labs Lp | METROGEL | metronidazole | GEL;TOPICAL | 021789-001 | Jun 30, 2005 | 6,881,726 | See Plans and Pricing |
Galderma Labs | CLOBEX | clobetasol propionate | SHAMPOO;TOPICAL | 021644-001 | Feb 5, 2004 | 7,316,810 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GALDERMA LABS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Lotion | 0.05% | ➤ Subscribe | 2006-03-27 |
➤ Subscribe | Topical Shampoo | 0.05% | ➤ Subscribe | 2008-01-09 |
➤ Subscribe | Topical Gel | 0.30% | ➤ Subscribe | 2009-09-15 |
➤ Subscribe | Gel | 0.1%/2.5% | ➤ Subscribe | 2011-12-30 |
➤ Subscribe | Topical Gel | 0.33% | ➤ Subscribe | 2014-12-15 |
➤ Subscribe | Gel | 0.3%/2.5% | ➤ Subscribe | 2016-05-04 |
➤ Subscribe | Spray | 0.05% | ➤ Subscribe | 2008-09-29 |
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2008-12-11 |
➤ Subscribe | Cream | 1% | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Topical Gel | 1% | ➤ Subscribe | 2008-10-21 |
International Patents for Galderma Labs Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | PA05011208 | See Plans and Pricing |
Brazil | PI0214264 | See Plans and Pricing |
Japan | 2015523342 | See Plans and Pricing |
European Patent Office | 1712236 | See Plans and Pricing |
Russian Federation | 2001101891 | See Plans and Pricing |
Singapore | 189896 | See Plans and Pricing |
European Patent Office | 1485080 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Galderma Labs Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0733366 | SPC/GB98/031 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
2137537 | 92487 | Luxembourg | See Plans and Pricing | PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140203 |
1948158 | 300810 | Netherlands | See Plans and Pricing | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, IE. TRINATRIURA (3-((LS,3R)-L-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONYL-L-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-ETHYL-2'-(PENTANOYL(2"-(TETRAZOL-5-YLAAT)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT) HEMIPENTAHYDRAAT; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123 |
2395002 | 300812 | Netherlands | See Plans and Pricing | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124 |
0306228 | SPC/GB01/002 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
1831149 | LUC00162 | Luxembourg | See Plans and Pricing | PRODUCT NAME: TRIFAROTENE, EVENTUELLEMENT SOUS LA FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: PL 105590/0071 - 0001 20200519 |
0253310 | SPC/GB95/010 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.